IntraGel, is a pharma company located at NGT3VC, Nazareth. IntraGel is focused on the field of long-acting and local delivery of “challenging” small molecule drugs, peptides and other anti-neoplasm agents. IntraGel has developed a unique injectable polymeric platform for sustained release (SRGel), that solidifies once injected into the body. Within 24hrs the gel starts to breakdown slowly and over weeks releasing the trapped drug/agent to the surrounding area. Intragel platform is fatty acid based making it hydrophobic and solventless, making it versatile platform that can cover wide range of drugs, including the most sensitive or insoluble ones. IntraGel’s oncology market potential is a multibillion dollar ($). Intragel is currently targeting head and neck cancer (HNC), having high unmet met need of 50% unfit patients for conventional systemic chemotherapy. IntraGel’s platform facilitated a simple application through direct intratumoral injection. Intragel technology long-acting effect lasts over weeks, with minimal to no systemic toxicity, giving those unfit patients a second chance to fight cancer back.
